HOOKIPA Pharma (HOOK)
(Delayed Data from NSDQ)
$4.74 USD
+0.02 (0.42%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.74 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
HOOK 4.74 +0.02(0.42%)
Will HOOK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HOOK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HOOK
Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet
Generation Bio Co. (GBIO) Reports Q2 Loss, Tops Revenue Estimates
HOOK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe HOOKIPA Pharma (HOOK) Could Rally 634.38%: Here's is How to Trade
Will HOOKIPA Pharma Inc. (HOOK) Report Negative Q2 Earnings? What You Should Know
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
Other News for HOOK
HOOKIPA Pharma Announces Board of Directors Changes
Hookipa Pharma appoints O'Neill as non-executive chair of board
HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Replimune Group (REPL) and Hookipa Pharma (HOOK)
HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Misses Revenue for Q2 2024